Drug Trial Radar · NCT07291232
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
80
Actual
Start
Nov 19, 2025
Primary completion
Apr 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Dec 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.
Conditions
- Obesity
Interventions
ABBV-295Drug
Subcutaneous Injections
PlaceboDrug
Subcutaneous Injections
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 194 days
- Number of Participants with Abnormal Change From Baseline in Vital Sign MeasurementsTime frame: Up to approximately 194 days
- Number of Participants with Change from Baseline in Electrocardiogram (ECG)Time frame: Up to approximately 194 days
- Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be AssessedTime frame: Up to approximately 194 days
- Maximum Observed Plasma Concentration (Cmax) of ABBV-295Time frame: Up to approximately 194 days
- Time to Cmax (Tmax) of ABBV-295Time frame: Up to approximately 194 days
- Trough plasma concentration (Ctrough) of ABBV-295Time frame: Up to approximately 194 days
- Apparent terminal phase elimination rate constant (BETA) of ABBV-295Time frame: Up to approximately 194 days
- Terminal phase elimination half-life (t1/2) of ABBV-295Time frame: Up to approximately 194 days
- Area under the plasma concentration-time curve (AUC) of ABBV-295Time frame: Up to approximately 194 days
- Area under the plasma concentration-time curve over the dosing interval (AUCtau) of ABBV-295Time frame: Up to approximately 194 days
- Dose Normalized Cmax of ABBV-295Time frame: Up to approximately 194 days
- Dose Normalized AUC of ABBV-295Time frame: Up to approximately 194 days
- Incidence of Anti-Drug Antibodies (ADAs)Time frame: Up to approximately 194 days
- Percent Change in Body Weight From BaselineTime frame: Up to approximately 194 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
CenExel Act- Anaheim Clinical Trials /ID# 283200
Anaheim, California
Acpru /Id# 278624
Grayslake, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.